Management of RAASi-associated hyperkalemia in patients with cardiovascular disease.

"Conflict of interest José Silva-Cardoso has received speaker and consultant fees, or advisory board participation fees, or investigational grants from Abbott, AstraZeneca Pharmaceuticals, Bial, Boehringer Ingelheim, Menarini, Merck Serono, Merck Sharp & Dohme, Novartis, Orion, Pfizer, Sanofi, Servier, and Vifor Pharma. Dulce Brito has received speaker and consultant fees or investigational grants from AstraZeneca Pharmaceuticals, Boehringer Ingelheim, Novartis, Orion, Pfizer, Roche Diagnostics, Sanofi, Servier, and Vifor Pharma. João Miguel Frazão has received speaker and consultant fees from Amgen Biopharmaceuticals and Vifor Pharma. Aníbal Ferreira has received speaker and consultant fees or investigational grants from Amgen Biopharmaceuticals, Astellas, Boehringer Ingelheim, Mundipharma, Sanofi, Shire, Vifor Pharma. Paulo Bettencourt has received speaker and consultant fees from OM PHARMA, Servier, and AstraZeneca and an investigational grant from Roche Diagnostics. Patrícia Branco has received speaker and consultant fees from AstraZeneca Pharmaceuticals, Bayer, Baxter, Boehringer Ingelheim, Medtronic, Mundipharma, and Vifor Pharma. Cândida Fonseca has received speaker and consultant fees, or investigational grants, from AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim, Merck Serono, Novartis, Orion, Pfizer, Sanofi, Servier, and Vifor Pharma."

"Funding This work was supported by Vifor Pharma, Portugal, via an educational grant."